Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
In vivo bradykinin B2 receptor activation reduces renal fibrosis
Joost P. Schanstra, … , Jean-Pierre Girolami, Jean-Loup Bascands
Joost P. Schanstra, … , Jean-Pierre Girolami, Jean-Loup Bascands
Published August 1, 2002
Citation Information: J Clin Invest. 2002;110(3):371-379. https://doi.org/10.1172/JCI15493.
View: Text | PDF
Article Genetics

In vivo bradykinin B2 receptor activation reduces renal fibrosis

  • Text
  • PDF
Abstract

Research Article

Authors

Joost P. Schanstra, Eric Neau, Pascale Drogoz, Miguel A. Arevalo Gomez, José Miguel Lopez Novoa, Denis Calise, Christiane Pecher, Michael Bader, Jean-Pierre Girolami, Jean-Loup Bascands

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
(a) Effect of bradykinin (24 hours at 0.1μM) on PA activity from primary...
(a) Effect of bradykinin (24 hours at 0.1μM) on PA activity from primary culture proximal tubular cells pretreated (24 hours) with TNF-α (150 U/ml) and IFN-γ (500 U/ml) (boxed part of the figure) or non-pretreated. TGF-β, 10 ng/ml; HOE-140, 0.1 μM; NG-nitro-L-arginine methyl ester (L-NAME), 0.5 mM; lovastatine, 5 μM. (b) Western blot of B2 receptor (B2R) expression. (c) Increase in intracellular calcium ([Ca2+]i) following bradykinin (0.1 μM) stimulation (time of stimulation 5 minutes). Values are mean ± SEM of five different experiments. *P < 0.05 compared with control cells. Representative blots or traces are shown.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts